The Swedish contract manufacturing organisation (CMO) raised the cash by issuing 2,250,000 Class B which attracted “a few well known institutional investors.”
Recipharm said the move would diversify its shareholder base and “raise capital in a time efficient manner to partly finance acquisition, previously announced during the fourth quarter 2015.”
The acquisition in question was the CMOs payment of INR 6712m ($103m) for a 74% holding in Nitin Lifesciences Limited - a sterile injectables manufacturing organisation headquartered at Karnal in Northern India.
At the time Recipharm executive vice president Mark Quick told us the investment in Nitin was designed to meet customer demand for high quality manufacturing in India.
The Nitin deal is part of the aggressive growth strategy Recipharma adopted when it went public in June 2014.
The Nitin deal is still yet to close and so Recipharm has not started on integration, but CEO Thomas Eldered told this publication "the planning looks promising."
He added: "This raising was related to already announced acquisitions, including Indian Nitin but also the transaction with Alcon that was completed at year end. We continue to pursue our growth plan and we are certainly looking for further acquisition opportunities and indeed hope to close further transactions this year."